Meeting
2017 ASCO Annual Meeting
Cost-effectiveness of nivolumab for treatment of platinum-resistant recurrent or metastatic squamous cell carcinoma of the head and neck.
Authors
Kate Carroll
University of California, San Diego Moores Cancer Center, San Diego School of Medicine, La Jolla, CA
Kate Carroll , Kathryn Ries Tringale , Kaveh Zakeri , Assuntina Gesualda Sacco , Linda Barnachea , James Don Murphy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 35, 2017 (suppl; abstr 6026)
DOI
10.1200/JCO.2017.35.15_suppl.6026
Abstract #
6026
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.
First Author: Nabil F. Saba
Poster
2017 ASCO Annual Meeting
Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.
First Author: Robert L. Ferris
Poster
2017 ASCO Annual Meeting
Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy.
First Author: Maura L. Gillison
Poster
2023 ASCO Annual Meeting
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.
First Author: Douglas Adkins